Antidepressants for Elderly With Anxiety: What Is Safest?

What is the best antidepressant for treating anxiety in the elderly?

The best antidepressant for an older person is the one whose expected benefit and risks fit that person’s health and medication list. The American Geriatrics Society Health in Aging Foundation describes SSRIs as commonly used for anxiety in older adults and says an SNRI may be considered if an SSRI does not work.

A clinical review by Crocco and colleagues identifies antidepressants as first-line medication treatment for late-life anxiety, with SSRIs and SNRIs commonly used. It describes evidence of benefit from escitalopram and citalopram in older adults. These findings do not establish one medicine as best for everyone: interactions, other conditions, and side-effect risks alter the balance.

Some alternatives have added concerns. The review notes that tricyclic antidepressants and monoamine oxidase inhibitors have less favorable safety profiles for late-life treatment. Paroxetine can inhibit CYP2D6 and has anticholinergic effects linked to confusion, constipation, blurred vision, or urinary retention. The same review flags low sodium, falls and fractures, and increased upper gastrointestinal bleeding when an SSRI is combined with an NSAID.

Medication is not the only treatment path. The AGS says treatment can include psychotherapy, medication, or both, based on symptom severity, effect on daily life, and the person’s preferences. It notes that cognitive-behavioral therapy can help with several anxiety disorders. Benzodiazepines are not recommended as a first treatment for older adults because they can increase falls and cognitive impairment risk.

Should an 80-year-old take antidepressants for anxiety?

An 80-year-old may be treated with an antidepressant for anxiety when a prescriber judges that the likely benefit outweighs the risks for that person. Age alone does not settle the question; health conditions, medicines, daily function, symptoms, and preferences all matter.

Risk review is part of the decision, not an afterthought. According to a clinical review by van Poelgeest and colleagues, a meta-analysis covering 248 studies found an association between antidepressant use and increased falls: pooled odds ratio 1.57, with a 95% confidence interval of 1.43–1.74. The review cautions that fall risk has multiple causes and untreated illness can also contribute. These figures describe an association across studies; they do not predict an individual’s outcome.

The first weeks after starting treatment or raising a dose deserve attention, since the review says fall risk appears greatest then. Dizziness, blood-pressure changes on standing, low sodium, sedation, and muscle weakness can make steadiness worse. Diuretics and kidney disease can add to low-sodium risk. New confusion or weakness should be discussed with the prescriber rather than assumed to be part of aging.

Which antidepressants are generally considered safer for older adults?

SSRIs and SNRIs are commonly considered before older antidepressant classes, but neither class is risk-free. Which option fits depends on the person’s medical history and other medicines, including drugs that affect blood pressure, heart rhythm, bleeding, or sodium.

Citalopram illustrates why a familiar option still needs individual review. Its prescribing information sets a maximum recommended dose of 20 mg once daily for people older than 60, and warns that it can prolong the QT interval in a dose-dependent way. The label advises avoiding it in certain heart conditions and with other medicines that prolong QT, and it warns about low sodium, bleeding interactions, and serotonin syndrome when combined with other serotonergic medicines. The dose limit is a prescribing-label fact, not a recommendation for an individual.

Other differences matter. Crocco and colleagues report that venlafaxine can raise blood pressure and duloxetine calls for caution in hepatic impairment. Paroxetine’s anticholinergic effects can be a concern when confusion, constipation, vision changes, or urinary retention are relevant. These distinctions make the medication list and medical history central to choosing among options.

Fall evidence adds context rather than a simple ranking. The van Poelgeest review reports class-specific estimates of increased falls for SSRIs and tricyclic antidepressants, while cautioning that risks vary and illness itself can contribute. The useful question is not which class has a universally safe label, but which specific medicine can be monitored against the person’s risks.

How long can antidepressants take to help anxiety in an older person?

The time to benefit varies, so the prescriber should set expectations and a follow-up plan for the specific medicine. The National Institute on Aging recommends asking when a medicine should start working and how to recognize whether it is working. A dementia-related trial summarized in the Crocco anxiety review found reduced anxiety symptoms after 9 weeks of citalopram compared with placebo; that result is one study in a specific population, not a general timetable for every older adult.

Track change in the symptoms that led to treatment, alongside side effects and daily function. A medicine that has not yet helped calls for a planned review, not an unsupervised dose change or abrupt stop. Citalopram’s label advises gradual dose reduction rather than stopping abruptly whenever possible.

A practical prescriber-visit checklist helps make that review safer:

• Bring a complete list of prescription medicines, over-the-counter medicines, vitamins, supplements, and herbal remedies.
• Describe prior falls, dizziness, fainting, or concerns about sodium; note kidney or liver conditions and any diuretic use.
• Share heart history and ask whether any medicines affect heart rhythm or blood pressure.
• Agree on what improvement to track, which side effects to watch for, and when to follow up.
• Ask whether the medicine can be stopped abruptly and what to do if a dose or treatment change causes problems.

The NIA emphasizes a complete medicine list because older adults often take medicines for several conditions, which increases the chance of side effects and interactions. Its medication-safety guidance also recommends asking whether a medicine interacts with others and what side effects to watch for.

When anxiety occurs with dementia or cognitive impairment

Anxiety alongside dementia needs its own treatment discussion. A review by Crocco and colleagues on neuropsychiatric symptoms in major neurocognitive disorders says evidence and treatment decisions for these symptoms require specific consideration, and that pharmacotherapy evidence is limited. It recommends cautious prescribing and ongoing reassessment.

That review also notes that SSRIs can increase risks of falls, fractures, and low sodium, while citalopram and escitalopram raise QT-prolongation concerns. A result in one Alzheimer’s disease trial does not settle treatment for every person with dementia. Changes in cognition, mobility, and other symptoms belong in the follow-up plan.